AVBP - ArriVent BioPharma, Inc. Common Stock
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$44.00
DETAILS
HIGH:
$45.00
LOW:
$43.00
MEDIAN:
$44.00
CONSENSUS:
$44.00
UPSIDE:
64.61%
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses | |||||
| R&D Expenses | 153.4 | 79.0 | 64.9 | 30.4 | 6.4 |
| SG&A Expenses | 24.2 | 15.3 | 9.7 | 6.5 | 2.3 |
| Other Expenses | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses | 177.5 | 94.3 | 74.6 | 36.9 | 8.7 |
| Operating Income | |||||
| Operating Income | (177.5) | (94.3) | (74.6) | (36.9) | (8.7) |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 11.2 | 13.8 | 5.3 | 0 | 0 |
| Profitability | |||||
| EBITDA | (177.5) | (80.5) | (74.6) | 0 | (51.6) |
| EBIT | (177.5) | (80.5) | (74.6) | (36.9) | (51.6) |
| Income Before Tax | (166.3) | (80.5) | (69.3) | (36.9) | (51.6) |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (166.3) | (80.5) | (69.3) | (36.9) | (51.6) |
| Per Share Data | |||||
| EPS (Basic) | -4.32 | -2.56 | -2.17 | -1.10 | -40.44 |
| EPS (Diluted) | -4.32 | -2.56 | -2.17 | -1.10 | -40.44 |
| Shares Outstanding | 38.5 | 31.5 | 32.0 | 33.5 | 1.3 |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Current Assets | |||||
| Cash & Cash Equivalents | 45.5 | 74.3 | 150.4 | 163.4 | 37.3 |
| Short-Term Investments | 267.3 | 144.6 | 0 | 0 | 0 |
| Net Receivables | 0 | 0.5 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 20.1 | 0 | 9.2 | 18.9 | 5.6 |
| Total Current Assets | 332.9 | 227.0 | 160.0 | 182.6 | 43.0 |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 0.0 | 0.2 | 0.3 | 0.1 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 47.7 | 0 | 0 | 0 |
| Other Non-Current Assets | 0.3 | 0.1 | 2.8 | 0.1 | 0.1 |
| Total Non-Current Assets | 0.3 | 48.0 | 3.1 | 0.2 | 0.1 |
| Total Assets | 333.2 | 274.9 | 163.1 | 182.8 | 43.0 |
| Current Liabilities | |||||
| Account Payables | 5.9 | 3.8 | 4.5 | 3.1 | 0.3 |
| Short-Term Debt | 0.0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 20.0 | 4.2 | 0 | 0 | 0 |
| Total Current Liabilities | 25.9 | 17.3 | 11.6 | 8.4 | 1.8 |
| Non-Current Liabilities | |||||
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Liabilities | 0 | 0.0 | 0.2 | 0.0 | 0 |
| Total Liabilities | 25.9 | 17.3 | 11.8 | 8.4 | 1.8 |
| Stockholders' Equity | |||||
| Common Stock | 0.0 | 0.0 | 0 | 0 | 0 |
| Retained Earnings | (404.6) | (238.3) | (157.8) | (88.5) | (51.6) |
| Accumulated Other Comprehensive Income | 0.0 | (0.2) | 0 | 0 | (0.0) |
| Total Stockholders' Equity | 307.2 | 257.7 | 151.3 | 174.5 | 41.2 |
| Total Liabilities & Equity | 333.2 | 274.9 | 163.1 | 182.8 | 43.0 |
| Debt Metrics | |||||
| Total Debt | 0.0 | 0.2 | 0.3 | 0.1 | 0 |
| Net Debt | (45.5) | (74.1) | (150.1) | (163.2) | (37.3) |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | (166.3) | (80.5) | (69.3) | (36.9) | (51.6) |
| Depreciation & Amortization | (3.0) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 12.5 | 3.2 | 0.9 | 0.4 | 0 |
| Change in Working Capital | (3.8) | 7.1 | 12.6 | (7.1) | (3.9) |
| Other Non-Cash Items | 0 | 0 | 0 | 0 | 43.0 |
| Operating Cash Flow | (160.6) | (70.2) | (55.8) | (43.6) | (12.6) |
| Investing Activities | |||||
| Capital Expenditure | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (272.9) | (194.2) | (25) | 0 | 0 |
| Sales/Maturities of Investments | 201.7 | 1.7 | 25 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | (40) |
| Investing Cash Flow | (71.2) | (192.5) | 0 | 0 | (40) |
| Financing Activities | |||||
| Net Debt Issuance | 0 | 0 | 0 | 0 | 0 |
| Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (0.1) | 0.6 | (2.1) | 0.0 | 0 |
| Financing Cash Flow | 203.1 | 186.6 | 42.9 | 169.7 | 89.9 |
| Cash Position | |||||
| Net Change in Cash | (28.8) | (76.1) | (13.0) | 126.1 | 37.3 |
| Cash at Beginning | 74.3 | 150.4 | 163.4 | 37.3 | 0 |
| Cash at End | 45.5 | 74.3 | 150.4 | 163.4 | 37.3 |
| Free Cash Flow | (160.6) | (70.2) | (55.8) | (43.6) | (12.6) |
| Key Metrics | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | (177.5) | (94.3) | (74.6) | (36.9) | (8.7) |
| Net Income | (166.3) | (80.5) | (69.3) | (36.9) | (51.6) |
| EPS (Diluted) | -4.32 | -2.56 | -2.17 | -1.10 | -40.44 |
| Balance Sheet | |||||
| Cash & Equivalents | 45.5 | 74.3 | 150.4 | 163.4 | 37.3 |
| Total Assets | 333.2 | 274.9 | 163.1 | 182.8 | 43.0 |
| Total Debt | 0.0 | 0.2 | 0.3 | 0.1 | 0 |
| Stockholders' Equity | 307.2 | 257.7 | 151.3 | 174.5 | 41.2 |
| Cash Flow | |||||
| Operating Cash Flow | (160.6) | (70.2) | (55.8) | (43.6) | (12.6) |
| Capital Expenditure | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | (160.6) | (70.2) | (55.8) | (43.6) | (12.6) |